(HealthDay News) — For patients with primary lung neuroendocrine tumor (LNET), stereotactic body radiotherapy (SBRT) is well tolerated and provides locoregional control, according to research published in the International Journal of Radiation Oncology, Biology, Physics.
Researchers conducted a retrospective review of 48 tumors in 46 patients with a histologically confirmed diagnosis of LNET. Patients were treated nonoperatively with primary radiotherapy from 2006 to 2020.
The median tumor size was 2 cm, and the median age at treatment was 71 years. Thirty-two lesions were typical carcinoid histology, 7 were atypical, and 9 were indeterminate. The SBRT fractionation schedule given most often was 50 to 60 Gy in 5 daily fractions.
The overall survival rate was 64% at 3 years, 43% at 6 years, and 26% at 9 years. The progression-free survival rate was 88%, 78%, and 78%, respectively. The rate of local control was 97%, 91%, and 91%, respectively. One regional recurrence occurred in a paraesophageal lymph node. There were no grade 3 or higher toxicities.
“This is the largest series evaluating outcomes in patients with LNET treated with SBRT,” the researchers wrote. “This treatment is well tolerated, provides excellent locoregional control, and should be offered as an alternative to surgical resection for patients with early-stage LNET, particularly those who may not be ideal surgical candidates.”
Several study authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)